Functional and structural change in diabetic eyes. Interim results from an ongoing longitudinal prospective study

Acta Ophthalmologica

Volumn 91, Issue 7, 2013, Pages 672-677

  Hellgren, Karl Johan ^a,b   Bengtsson, Boel ^a   Agardh, Elisabet ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Center for Clinical Research   (Sweden)

Author keywords

diabetic retinopathy; longitudinal study design; perimetry; visual function

Indexed keywords

ADULT; ARTICLE; CORRELATION ANALYSIS; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EARLY TREATMENT DIABETIC RETINOPATHY STUDY SCALE; EYE PHOTOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORPHOLOGICAL TRAIT; PATIENT MONITORING; PERIMETRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; VISUAL ACUITY; VISUAL SYSTEM FUNCTION;

DIABETIC RETINOPATHY; LONGITUDINAL STUDY DESIGN; PERIMETRY; VISUAL FUNCTION;

ADULT; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; PROSPECTIVE STUDIES; RETINA; VISUAL ACUITY; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 84885956398     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2012.02508.x     Document Type: Article

References (31)

1. Afrashi F, Erakgun T, Kose S, Ardic K, &, Mentes J, (2003): Blue-on-yellow perimetry versus achromatic perimetry in type 1 diabetes patients without retinopathy. Diabetes Res Clin Pract 61: 7-11.
2. Agardh E, Stjernquist H, Heijl A, &, Bengtsson B, (2006): Visual acuity and perimetry as measures of visual function in diabetic macular oedema. Diabetologia 49: 200-206.
3. Bengtsson B, Lindgren A, Heijl A, Lindgren G, Asman P, &, Patella M, (1997): Perimetric probability maps to separate change caused by glaucoma from that caused by cataract. Acta Ophthalmol Scand 75: 184-188.
4. Bengtsson B, Heijl A, &, Agardh E, (2005): Visual fields correlate better than visual acuity to severity of diabetic retinopathy. Diabetologia 48: 2494-2500.
5. Bengtsson B, Hellgren KJ, &, Agardh E, (2008): Test-retest variability for standard automated perimetry and short-wavelength automated perimetry in diabetic patients. Acta Ophthalmol 86: 170-176.
6. Centers for Disease Control and Prevention (2011): National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Available from http://www.cdc.gov/diabetes/pubs/pdf/ ndfs-2011.pdf. Accessed January 2012.
7. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, &, Sjolie AK, (2008): Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 372: 1394-1402.
8. Csaky KG, Richman EA, &, Ferris FL 3rd, (2008): Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci 49: 479-489.
9. Diabetic Retinopathy Study research group (1981): Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 88: 583-600.
10. Early Treatment Diabetic Retinopathy Study research group (1985): Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103: 1796-1806.
11. Early Treatment Diabetic Retinopathy Study research group (1991): Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 98: 823-833.
12. Ferris FL 3rd, &, Bailey I, (1996): Standardizing the measurement of visual acuity for clinical research studies: Guidelines from the Eye Care Technology Forum. Ophthalmology 103: 181-182.
13. Fishman GA, Jacobson SG, Alexander KR, Cideciyan AV, Birch DG, Weleber RG, &, Hood DC, (2005): Outcome measures and their application in clinical trials for retinal degenerative diseases: outline, review, and perspective. Retina 25: 772-777.
14. Heijl A, Lindgren G, &, Olsson J, (1986): A package for the statistical analysis of visual fields. Doc Ophthalmol Proc Ser 49: 153-168.
15. Heijl A, Lindgren A, &, Lindgren G, (1989a): Test-retest variability in glaucomatous visual fields. Am J Ophthalmol 108: 130-135.
16. Heijl A, Lindgren G, &, Olsson J, (1989b): The effect of perimetric experience in normal subjects. Arch Ophthalmol 107: 81-86.
17. Henricsson M, &, Heijl A, (1994): Visual fields at different stages of diabetic retinopathy. Acta Ophthalmol (Copenh) 72: 560-569.
18. Heuer DK, Anderson DR, Knighton RW, Feuer WJ, &, Gressel MG, (1988): The influence of simulated light scattering on automated perimetric threshold measurements. Arch Ophthalmol 106: 1247-1251.
19. Kern TS, &, Barber AJ, (2008): Retinal ganglion cells in diabetes. J Physiol 586: 4401-4408.
20. Lam BL, Alward WL, &, Kolder HE, (1991): Effect of cataract on automated perimetry. Ophthalmology 98: 1066-1070.
21. Lobefalo L, Verrotti A, Mastropasqua L, Della Loggia G, Cherubini V, Morgese G, Gallenga PE, &, Chiarelli F, (1998): Blue-on-yellow and achromatic perimetry in diabetic children without retinopathy. Diabetes Care 21: 2003-2006.
22. Luckie R, Leese G, McAlpine R, MacEwen CJ, Baines PS, Morris AD, &, Ellis JD, (2007): Fear of visual loss in patients with diabetes: results of the prevalence of diabetic eye disease in Tayside, Scotland (P-DETS) study. Diabet Med 24: 1086-1092.
23. Mastropasqua L, Verrotti A, Lobefalo L, Chiarelli F, Verdesca G, &, Morgese G, (1995): Visual field defects in diabetic children without retinopathy. Relation between visual function and microalbuminuria. Acta Ophthalmol Scand 73: 125-128.
24. Mauer M, Zinman B, Gardiner R, et al., (2009): Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361: 40-51.
25. Mohamed Q, Gillies MC, &, Wong TY, (2007): Management of diabetic retinopathy: a systematic review. JAMA 298: 902-916.
26. PKC-DRS Study Group (2005): The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54: 2188-2197.
27. Sjolie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, &, Chaturvedi N, (2008): Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 372: 1385-1393.
28. Trick GL, Trick LR, &, Kilo C, (1990): Visual field defects in patients with insulin-dependent and noninsulin-dependent diabetes. Ophthalmology 97: 475-482.
29. Verrotti A, Lobefalo L, Altobelli E, Morgese G, Chiarelli F, &, Gallenga PE, (2001): Static perimetry and diabetic retinopathy: a long-term follow-up. Acta Diabetol 38: 99-105.
30. Villarroel M, Ciudin A, Hernandez C, &, Simo R, (2010): Neurodegeneration: an early event of diabetic retinopathy. World J Diabetes 1: 57-64.
31. Wild S, Roglic G, Green A, Sicree R, &, King H, (2004): Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053.